35380 Federal Register / Vol. 65, No. 107 / Friday, June 2, 2000 / Notices

Need and Use of Information Collection:

The NIDCD was established to support

biomedical and behavioral research and

research training in hearing, smell,

balance, taste, voice, speech and

language. Although minorities and

women will dominate the work force

within the next decade, both groups are

underrepresented in science and health

professional fields. Because of this

concern, the NIDCD, with assistance

from the Office of Research on Minority

Health, established the Partnership

Program in 1994 to increase the number

of minority scientists and health care

professionals doing research on

communication and communication

disorders. The proposed survey will

yield data about: (1) Reasons for

participation in the program; (2)

satisfaction of participants with the

program and (3) how participation in

the program has lead to the pursuit of

a career in the health field. This survey

will track the Partnership Program’s

success at increasing the number of

women and minorities who are

scientists. Frequency of Response: One.

Affected Public: Individuals. Type of

Respondent: Partnership Program

Participants. The annual reporting

burden is as follows: Estimated Number

of Respondents: 62; Estimated Number

of Responses per Respondent: 1;

Average Burden Hours Per Response:

0.5; and Estimated Total Annual Burden

Hours Requested: 15.5. The annualized

cost to respondents is estimated at:

$155. There are no Capital Costs to

report. There are no Operating or

Maintenance Costs to report.

Note: The following table is acceptable for

the Respondent and Burden Estimate

Information, if appropriate, instead of the

text as shown above.)

Type of respondents

Estimated

number of

respondents

Estimated

number of

responses

per respondent

Average

burden

hours per

response

Estimated

total annual

burden

hours requested

New Participants .............................................................................................................. 16 1 .25 4

Past Participants .............................................................................................................. 16 1 .25 4

Applicants ........................................................................................................................ 30 1 .25 7.5

Total .......................................................................................................................... 62 15.5

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for fulfillment of the NIDCD

mission, including whether the

information will have practical utility;

(2) the accuracy of the estimate of the

burden of the proposed data collection,

including the validity of the

methodology; (3) ways to enhance the

quality, utility, and clarity of the data

collection and (4) ways to minimize the

burden of the collection of information

on the respondents, including

appropriate use of automated collection

techniques and information technology.

Direct Comments to OMB

Written comments and/or suggestions

regarding the item(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time, should be directed to the

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, D.C. 20503, Attention:

Desk Officer for NIH. To request more

information on the proposed project or

to obtain a copy of the data collection

plans and instruments, contact: Mrs.

Kay C. Johnson-Graham, EEO Officer,

Office of Equal Employment

Opportunity, NIDCD, NIH, Building 31,

Room 3C08, 31 Center Drive, Bethesda,

MD 20892, or call non-toll-free number

(301) 402–6415 or E-mail your request,

including your address to:

<kayljohnson@ms.nidcd.nih.gov>.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

July 3, 2000.

Dated: May 23, 2000.

W. David Kerr,

Executive Officer, NIDCD.

[FR Doc. 00–13885 Filed 6–1–00; 8:45 am]

BILLING CODE 4140–01–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be listed at the end, and will be omitted

from the monthly listing thereafter.

This Notice is available on the

internet at the following website:

http://wmcare.samhsa.gov.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014, Fax: (301) 443–

3031.

Special Note: Please use the above address

for all surface mail and correspondence. For

all overnight mail service use the following

address: Division of Workplace Programs,

5515 Security Lane, Room 815, Rockville,

Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

Federal Register / Vol. 65, No. 107 / Friday, June 2, 2000 / Notices 35381

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln

Ave., West Allis, WI 53227, 414–

328–7840/800–877–7016,

(Formerly: Bayshore Clinical

Laboratory)

Advanced Toxicology Network, 3560

Air Center Cove, Suite 101,

Memphis, TN 38118, 901–794–

5770/888–290–1150,

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210,

615–255–2400

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery,

AL 36103, 800–541–4931/334–263–

5745

Alliance Laboratory Services, 3200

Burnet Ave., Cincinnati, OH 45229,

513–585–9000, (Formerly: Jewish

Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

20151, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave.,

Suite 250, Las Vegas, NV 89119–

5412, 702–733–7866/800–433–2750

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7,

Little Rock, AR 72205–7299, 501–

202–2783, (Formerly: Forensic

Toxicology Laboratory Baptist

Medical Center)

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–269–3093,

(Formerly: Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL,

Building 38-H, P. O. Box 88–6819,

Great Lakes, IL 60088–6819, 847–

688–2045/847–688–4171

Diagnostic Services Inc., dba DSI, 12700

Westlinks Drive, Fort Myers, FL

33913, 941–561–8200/800–735–

5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31602,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

206–386–2672/800–898–0180,

(Formerly: Laboratory of Pathology

of Seattle, Inc., DrugProof, Division

of Laboratory of Pathology of

Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Dynacare Kasper Medical Laboratories*,

14940–123 Ave., Edmonton,

Alberta, Canada T5V 1B4, 780–451–

3702/800–661–9876

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 662–

236–2609

Gamma-Dynacare Medical

Laboratories*, A Division of the

Gamma-Dynacare Laboratory

Partnership, 245 Pall Mall St.,

London, ONT, Canada N6A 1P4,

519–679–1630

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715,

608–267–6267

Hartford Hospital Toxicology

Laboratory, 80 Seymour St.,

Hartford, CT 06102–5037, 860–545–

6023

Integrated Regional Laboratories, 5361

NW 33rd Avenue, Fort Lauderdale,

FL 33309, 954–777–0018, 800–522–

0232, (Formerly: Cedars Medical

Center, Department of Pathology)

Kroll Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823,

(Formerly: Laboratory Specialists,

Inc.)

LabOne, Inc., 10101 Renner Blvd.,

Lenexa, KS 66219, 913–888–3927/

800–728–4064, (Formerly: Center

for Laboratory Services, a Division

of LabOne, Inc.)

Laboratory Corporation of America

Holdings, 1904 Alexander Drive,

Research Triangle Park, NC 27709,

919–572–6900/800–833–3984,

(Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem

Laboratories, Inc.; CompuChem

Laboratories, Inc., A Subsidiary of

Roche Biomedical Laboratory;

Roche CompuChem Laboratories,

Inc., A Member of the Roche Group)

Laboratory Corporation of America

Holdings, 4022 Willow Lake Blvd.,

Memphis, TN 38118, 901–795–

1515/800–233–6339, (Formerly:

LabCorp Occupational Testing

Services, Inc., MedExpress/National

Laboratory Center)

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 908–526–2400/800–437–

4986, (Formerly: Roche Biomedical

Laboratories, Inc.)

Marshfield Laboratories, Forensic

Toxicology Laboratory, 1000 North

Oak Ave., Marshfield, WI 54449,

715–389–3734/800–331–3734

MAXXAM Analytics Inc.*, 5540

McAdam Rd., Mississauga, ON,

Canada L4Z 1P1, 905–890–2555,

(Formerly: NOVAMANN (Ontario)

Inc.)

Medical College Hospitals Toxicology

Laboratory, Department of

Pathology, 3000 Arlington Ave.,

Toledo, OH 43699, 419–383–5213

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

651–636–7466/800–832–3244

MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR

97232, 503–413–5295/800–950–

5295

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, Minnesota 55417,

612–725–2088

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield,

CA 93304, 661–322–4250/800–350–

3515

NWT Drug Testing, 1141 E. 3900 South,

Salt Lake City, UT 84124, 801–293–

2300/800–322–3361, (Formerly:

NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc.,

1705 Center Street, Deer Park, TX

77536, 713–920–2559, (Formerly:

University of Texas Medical

Branch, Clinical Chemistry

Division; UTMB PathologyToxicology Laboratory)

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 541–687–2134

Pacific Toxicology Laboratories, 6160

Variel Ave., Woodland Hills, CA

91367, 818–598–3110/800–328–

6942, (Formerly: Centinela Hospital

Airport Toxicology Laboratory

Pathology Associates Medical

Laboratories, 11604 E. Indiana Ave.,

Spokane, WA 99206, 509–926–

2400/800–541–7891

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025,

650–328–6200/800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort

Worth, TX 76118, 817–215–8800,

(Formerly: Harris Medical

Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–339–0372/800–821–

3627

35382 Federal Register / Vol. 65, No. 107 / Friday, June 2, 2000 / Notices

Poisonlab, Inc., 7272 Clairemont Mesa

Blvd., San Diego, CA 92111, 858–

279–2600/800–882–7272

Quest Diagnostics Incorporated, 3175

Presidential Dr., Atlanta, GA 30340,

770–452–1590, (Formerly:

SmithKline Beecham Clinical

Laboratories, SmithKline BioScience Laboratories)

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI

48326, 248–373–9120/800–444–

0106, (Formerly: HealthCare/

Preferred Laboratories, HealthCare/

MetPath, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated,

National Center for Forensic

Science, 1901 Sulphur Spring Rd.,

Baltimore, MD 21227, 410–536–

1485, (Formerly: Maryland Medical

Laboratory, Inc., National Center for

Forensic Science, CORNING

National Center for Forensic

Science)

Quest Diagnostics Incorporated, 8000

Sovereign Row, Dallas, TX 75247,

214–638–1301, (Formerly:

SmithKline Beecham Clinical

Laboratories, SmithKline BioScience Laboratories)

Quest Diagnostics Incorporated, 4770

Regent Blvd., Irving, TX 75063,

972–916–3376/800–526–0947,

(Formerly: Damon Clinical

Laboratories, Damon/MetPath,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, 801

East Dixie Ave., Leesburg, FL

34748, 352–787–9006, (Formerly:

SmithKline Beecham Clinical

Laboratories, Doctors & Physicians

Laboratory)

Quest Diagnostics Incorporated, 400

Egypt Rd., Norristown, PA 19403,

610–631–4600/800–877–7484,

(Formerly: SmithKline Beecham

Clinical Laboratories, SmithKline

Bio-Science Laboratories)

Quest Diagnostics Incorporated, 506 E.

State Pkwy., Schaumburg, IL 60173,

800–669–6995/847–885–2010,

(Formerly: SmithKline Beecham

Clinical Laboratories, International

Toxicology Laboratories)

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA

92108–4406, 619–686–3200/800–

446–4728, (Formerly: Nichols

Institute, Nichols Institute

Substance Abuse Testing (NISAT),

CORNING Nichols Institute,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5590, (Formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratory)

Quest Diagnostics Incorporated, 7600

Tyrone Ave., Van Nuys, CA 91405,

818–989–2520/800–877–2520,

(Formerly: SmithKline Beecham

Clinical Laboratories)

San Diego Reference Laboratory, 6122

Nancy Ridge Dr., San Diego, CA

92121, 800–677–7995/858–677–

7970

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 25th St., Temple, TX 76504,

254–771–8379/800–749–3788

S.E.D. Medical Laboratories, 5601 Office

Blvd., Albuquerque, NM 87109,

505–727–6300/800–999–5227

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Tempe, AZ 85283,

602–438–8507/800–279–0027

Sparrow Health System, Toxicology

Testing Center, St. Lawrence

Campus, 1210 W. Saginaw, Lansing,

MI 48915, 517–377–0520,

(Formerly: St. Lawrence Hospital &

Healthcare System).

St. Anthony Hospital Toxicology

Laboratory, 1000 N. Lee St.,

Oklahoma City, OK 73101, 405–

272–7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia,

MO 65202, 573–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 818–996–7300 / 800–

339–4299, (Formerly: MetWest-BPL

Toxicology Laboratory)

Universal Toxicology Laboratories, LLC

10210 W. Highway 80, Midland,

Texas 79706, 915–561–8851/888–

953–8851

The following laboratory voluntarily

withdrew from the NLCP program,

effective May 16, 2000:

Quest Diagnostics Incorporated, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 412–920–

7733/800–574–2474, (Formerly: MedChek Laboratories, Inc., Med-Chek/

Damon, MetPath Laboratories,

CORNING Clinical Laboratories)

*The Standards Council of Canada

(SCC) voted to end its Laboratory

Accreditation Program for Substance

Abuse (LAPSA) effective May 12, 1998.

Laboratories certified through that

program were accredited to conduct

forensic urine drug testing as required

by U.S. Department of Transportation

(DOT) regulations. As of that date, the

certification of those accredited

Canadian laboratories will continue

under DOT authority. The responsibility

for conducting quarterly performance

testing plus periodic on-site inspections

of those LAPSA-accredited laboratories

was transferred to the U.S. DHHS, with

the DHHS’ National Laboratory

Certification Program (NLCP) contractor

continuing to have an active role in the

performance testing and laboratory

inspection processes. Other Canadian

laboratories wishing to be considered

for the NLCP may apply directly to the

NLCP contractor just as U.S. laboratories

do.

Upon finding a Canadian laboratory to

be qualified, the DHHS will recommend

that DOT certify the laboratory (Federal

Register, 16 July 1996) as meeting the

minimum standards of the ‘‘Mandatory

Guidelines for Workplace Drug Testing’’

(59 FR, 9 June 1994, Pages 29908–

29931). After receiving the DOT

certification, the laboratory will be

included in the monthly list of DHHS

certified laboratories and participate in

the NLCP certification maintenance

program.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 00–13798 Filed 6–1–00; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4557–N–22]

Federal Property Suitable as Facilities

To Assist the Homeless

AGENCY: Office of the Assistant

Secretary for Community Planning and

Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies

unutilized, underutilized, excess, and

surplus Federal property reviewed by

HUD for suitability for possible use to

assist the homeless.

EFFECTIVE DATE: June 2, 2000.

FOR FURTHER INFORMATION CONTACT:

Clifford Taffet, Department of Housing

and Urban Development, Room 7262,

451 Seventh Street SW, Washington, DC

20410; telephone (202) 708–1234; TTY

number for the hearing- and speechimpaired (202) 708–2565, (these

telephone numbers are not toll-free), or

call the toll-free Title V information line

at 1–800–927–7488.

SUPPLEMENTARY INFORMATION: In

accordance with the December 12, 1988